Takeda Pharmaceutical Company Limited (TAK)
| Market Cap | 57.89B +24.7% |
| Revenue (ttm) | 28.42B +3.1% |
| Net Income | -1.01B |
| EPS | -0.64 |
| Shares Out | 1.58B |
| PE Ratio | n/a |
| Forward PE | 33.24 |
| Dividend | $0.49 (2.73%) |
| Ex-Dividend Date | Mar 31, 2026 |
| Volume | 1,809,970 |
| Open | 18.00 |
| Previous Close | 18.03 |
| Day's Range | 17.96 - 18.11 |
| 52-Week Range | 12.99 - 18.90 |
| Beta | 0.10 |
| Analysts | Strong Buy |
| Price Target | 21.98 (+21.91%) |
| Earnings Date | Jul 30, 2026 |
About TAK
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, oncology, vaccines, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Takhzyro, Advate, Elaprase, Replagal, Vpriv, Adynovate/Adynovi, Livtencity, ADZYNMA, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Flexbumin, Adcetris, Leuplin/Enan... [Read more]
Analyst Summary
According to 3 analysts, the average rating for TAK stock is "Strong Buy." The 12-month stock price target is $21.98, which is an increase of 21.91% from the latest price.
News
Takeda receives FDA approval of NDA for Mimrylo
Takeda (TAK) announced U.S. FDA approval of the New Drug Application for Mimrylo for the treatment of erythrocytosis in adults with polycythemia vera, a blood cancer.
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for...
US FDA approves Takeda, Protagonist's drug for rare blood cancer
The U.S. Food and Drug Administration has approved a first-of-its-kind drug from Takeda Pharmaceutical and Protagonist Therapeutics to treat a rare blood cancer, the health regulator said o...
Takeda announces Japan MHLW approval for Orzeyful
Takeda (TAK) announced that the Japanese Ministry of Health, Labour and Welfare, or MHLW, approved the use of Orzeyful for the treatment of narcolepsy type 1 in adults. Orzeyful is…
ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE:TAK) announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved the use of ORZEYFUL (oveporexton) for ...
Takeda award from Veterans Affairs posted to SAM.gov site
A contract award dated August 7 from Department of Veterans Affairs to Takeda (TAK) Pharmaceuticals America was posted to the SAM.gov website. The total contract value for the base and…
FDA approves Takeda’s Orzeyful to treat narcolepsy type 1
Takeda (TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL, an oral orexin receptor 2 agonist, for the treatment of narcolepsy type 1 in adults. The persistent…
U.S. FDA Approves Takeda's ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2...
US FDA approves Takeda's sleep disorder pill
The FDA has approved Takeda Pharmaceuticals' oral drug for narcolepsy, the U.S. health regulator said on Wednesday, backing the first treatment that targets all the symptoms of the rare sleep disord...
Keros Therapeutics to receive $20M elritercept milestone payment from Takeda
Keros Therapeutics (KROS) announced that it will receive a $20M development milestone payment under the terms of the license agreement of elritercept with partner Takeda (TAK), following the dosing of...
Takeda Pharmaceutical Q1 Earnings Call Highlights
Takeda Pharmaceutical NYSE: TAK said its first-quarter fiscal 2026 results were in line with its full-year outlook as growth from core brands and newer products largely offset expected declines in its...
Takeda Pharmaceutical Company Earnings Call Transcript: Q1 2027
Q1 FY2026 results were in line with expectations, with core revenue and profit slightly down at CER but strong FX gains. Launch preparations for ORZEYFUL, rusfertide, and zasocitinib are progressing, and full-year guidance is reaffirmed.
Takeda Pharmaceutical Company Quarterly report: Q1 2027
Takeda Pharmaceutical Company has published its Q1 2027 quarterly earnings report on July 30, 2026.
Takeda Pharmaceutical Company Slides: Q1 2027
Takeda Pharmaceutical Company has posted slides in relation to its Q1 2027 quarterly earnings report, which was published on July 30, 2026.
Takeda Announces FY2026 First Quarter Results, Near-Term Launch Preparations and Pipeline Progress on Track
OSAKA, Japan--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE:TAK) announced financial results for the first quarter of fiscal year 2026 (April 1, 2026 to June 30, 2026), marking a period of disciplined exec...
Takeda dengue vaccine receives marketing authorization from India DCGI
Takeda (TAK) announced that India’s Drug Controller General of India, or DCGI, has granted marketing authorization for Takeda’s dengue vaccine for the prevention of dengue disease in individuals four ...
Takeda's QDENGA becomes first dengue vaccine approved in India
Japanese drugmaker Takeda Pharmaceutical's dengue vaccine QDENGA has been approved by India's drug regulator, making it the first dengue vaccine to be approved in the country, the compan...
Takeda's Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective and p...
Takeda, the Indoensian Government announce collaboration
Takeda (TAK) and the Indonesian Government announced a collaboration aimed at strengthening Indonesia’s plasma ecosystem and supporting equitable access to plasma-derived medicinal products, PDMPs, in...
Takeda and the Indonesian Government Announce Landmark Collaboration to Strengthen Healthcare Resilience and Expand Access to Lifesaving Plasma-Derived Medicinal Products
OSAKA, Japan & CAMBRIDGE, Mass. & JAKARTA, Indonesia--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) and the Indonesian Government (the Ministry of Health, the Ministry of Investment and Downstream Indus...
Insilico Medicine Announces Collaboration with Takeda to Advance Strategic AI Drug Discovery
Partnership to leverage Pharma.AI platform for novel drug candidates across Takeda's therapeutic areas CAMBRIDGE, Mass., July 1, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico" HKEX:3696), a leader...
Takeda, InSilico Strike AI Drug-Discovery Deal Worth Up to $600 Million
Takeda is set to pay InSilico to use its proprietary Pharma. AI platform to advance drug candidates across several therapeutic areas, according to people familiar with the matter.
Takeda CEO Christophe Weber retires, Julie Kim succeeds
Takeda (TAK) announced that Julie Kim was officially appointed Takeda’s representative director, president and CEO. During the annual general meeting of shareholders, which took place in Osaka, Japan,...
Takeda Announces New Assignments of Directors and Appointment of Julie Kim as Representative Director, President and CEO
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--In the final step of its 18-month CEO transition, Takeda (TOKYO:4502/NYSE:TAK) today announced that Julie Kim was officially appointed Takeda's Repres...
Takeda Canada reports ‘positive’ results from Phase 3 study of zasocitinib
Takeda (TAK) Canada is pleased to announce positive topline results for the Phase 3, randomized, multicenter, double-blind study comparing zasocitinib, an investigational, next-generation, highly sele...